New weekly drug aims to fix Chemo-Induced low platelets
NCT ID NCT06759636
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called romiplostim N01, given as a weekly shot, against a standard daily shot (rhIL-11) for cancer patients whose platelet counts drop due to treatment. About 88 adults with various cancers and low platelets will be randomly assigned to one of the two drugs. The main goal is to see which drug raises platelet counts faster and more safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Romiplostim N01 (a platelet-boosting drug)
- What this could lead to
- If it works, this could offer a more effective and convenient weekly injection to manage low platelets caused by cancer therapy.
- What could go wrong
- This is a relatively small Phase 3 trial (88 people), and the drug may not prove superior to the existing daily injection. Risks include potential side effects like bone marrow changes or blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTIT: CANCER THERAPY INDUCED THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China